Scandinavian Working Papers in Economics
Memorandum,
Oslo University, Department of Economics
No 10/2009: Choosing among Competing Blockbusters: Does the Identity of the Third-party Payer Matter for Prescribing Doctors?
Dag Morten Dalen, Enrico Sorisio and Steinar Strøm ()
Additional contact information
Dag Morten Dalen: Norwegian School of Management BI
Enrico Sorisio: PharmaNess and University of Oslo
Steinar Strøm: Dept. of Economics, University of Oslo, Postal: Department of Economics, University of Oslo, P.O Box 1095 Blindern, N-0317 Oslo, Norway
Abstract: TNF-alpha inhibitors represent one of the most important areas of biopharmaceuticals by sales, with three blockbusters accounting for 8 % of total pharmaceutical sale in Norway. With use of a unique natural policy experiment in Norway, this paper examines to what extent the identity of the third-party payer affects doctors choice between the three available drugs. We are able to investigate to what extent the price responsiveness of prescription choices is affected when the identity of the third-party payer changes. The three dominating drugs in this market, Enbrel, Remicade, and Humira, are substitutes, but have had different and varying funding schemes - hospitals and the national insurance plan. We find that treatment choices are price responsive, and that the price response increases when the doctor’s affiliated hospital covers the cost instead of a traditional fee-for-service insurance plan.
Keywords: Pharmaceuticals; discrete choice model; funding schemes
27 pages, May 14, 2009
Full text files
Memo-10-2009.pdf
Questions (including download problems) about the papers in this series should be directed to Mari Strønstad Øverås ()
Report other problems with accessing this service to Sune Karlsson ().
RePEc:hhs:osloec:2009_010This page generated on 2024-09-13 22:16:45.